Response of untreated stage IV Wilms' tumor to single dose carboplatin assessed by “up front” window therapy
Version of Record online: 20 JUL 2006
Copyright © 1995 Wiley-Liss, Inc., A Wiley Company
Medical and Pediatric Oncology
Volume 25, Issue 1, pages 8–11, July 1995
How to Cite
Zoubek, A., Kajtar, P., Flucher-Wolfram, B., Holzinger, B., Mostbeck, G., Thun-Hohenstein, L., Fink, F. M., Urban, C., Mutz, I., Schuler, D. and Gadner, H. (1995), Response of untreated stage IV Wilms' tumor to single dose carboplatin assessed by “up front” window therapy. Med. Pediatr. Oncol., 25: 8–11. doi: 10.1002/mpo.2950250103
- Issue online: 20 JUL 2006
- Version of Record online: 20 JUL 2006
- Manuscript Accepted: 30 APR 1994
- Manuscript Received: 2 FEB 1994
- “Österreichische Kinderkrebshilfe” and by Bristol-Myers Squibb, Vienna, Austria
- Wilms' tumor stage IV;
- carboplatin (CBDCA);
- preoperative chemotherapy
A total of nine children with previously untreated stage IV Wilms' tumor of favorable histology were treated according to the Austrian/Hungarian Wilms' Tumor Protocol 89 and received a preoperative single dose of carboplatin as an “up front” window therapy. The treatment consisted of carboplatin as a single-dose of 600 mg/m2 over 30 minutes on day 1. Response evaluation by chest X-ray, serial CT scans, and sonography was performed on day 22. Investigation of the abdominal tumors revealed seven partial responses (78%), one nonresponse, and one progressive disease with a median tumor volume reduction of 62%. Response of metastases evaluated by CT scans was as follows: four complete remission, four partial response, and one nonresponse.
Thrombocytopenia (WHO grade III 1, grade II 2, grade I 2) and leukocytopenia (WHO grade II 1, grade I 5) were the main side effects. No renal or liver toxicity were observed.
The overall response rate after a preoperative single-dose of 600 mg/m2 carboplatin in untreated patients with stage IV Wilms' tumor is encouraging and the toxicity acceptable. This data indicate that carboplatin seems to be an additional effective drug in patients with previously untreated Wilms' tumor of favorable histology. © 1995 Wiley-Liss, Inc.